Workflow
TearCare® System
icon
Search documents
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Globenewswire· 2025-08-26 20:05
Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to improve patient care and transform treatment paradigms [1][3] - The company will present at the Morgan Stanley Global Healthcare Conference on September 10, 2025, at 10:50 am PT / 1:50 pm ET [2] Company Overview - Sight Sciences develops minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System and OMNI® Edge Surgical System are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
Globenewswire· 2025-07-24 20:05
Core Insights - Sight Sciences, Inc. will report its financial results for Q2 2025 on August 7, 2025, after market close [1] - A conference call to discuss the results will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Company Overview - Sight Sciences is an eyecare technology company focused on innovative and interventional solutions to improve patient care [3] - The company develops minimally invasive or non-invasive technologies targeting prevalent eye diseases, aiming to enhance treatment paradigms [3] - Key products include the OMNI® Surgical System and OMNI® Edge Surgical System for glaucoma treatment, and the TearCare® System for evaporative dry eye disease [3]
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
Globenewswire· 2025-05-14 20:05
Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at the Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025 [2] Company Overview - Sight Sciences specializes in minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System and OMNI® Edge Surgical System are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease, addressing the leading cause of dry eye [3]
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
Globenewswire· 2025-05-08 20:05
Core Insights - Sight Sciences, Inc. reported a revenue of $17.5 million for Q1 2025, a 9% decrease compared to the same period in the previous year, primarily due to lower Surgical Glaucoma revenue and fewer Dry Eye product sales [4][7][10] - The company reaffirmed its revenue guidance for the full year 2025, expecting approximately $70.0 million to $75.0 million, reflecting a 6% to 12% decline compared to 2024 [10] - Adjusted operating expenses guidance for 2025 has improved, now expected to be approximately $101.0 million to $105.0 million, representing a 0% to 4% increase compared to 2024 [11] Financial Performance - Surgical Glaucoma revenue was $17.1 million, down 6% year-over-year, attributed to a 10% decrease in account utilization due to Medicare restrictions [4][10] - Dry Eye revenue decreased to $0.4 million from $1.0 million in the prior year, mainly due to a focus on reimbursed market access for TearCare [4][10] - Gross profit for Q1 2025 was $15.1 million, with a gross margin of 86%, unchanged from the previous year [5][7] Operating Expenses - Total operating expenses were $29.0 million, a 7% decrease from $31.2 million in the prior year, driven by lower legal expenses [6][7] - Research and development expenses were $4.4 million, down 4% year-over-year, while selling, general, and administrative expenses decreased by 8% to $24.5 million [6][7] Net Loss and Cash Position - The net loss for Q1 2025 was $14.2 million, or $0.28 per share, an improvement from a net loss of $16.3 million, or $0.33 per share, in the same period last year [8][29] - As of March 31, 2025, cash and cash equivalents totaled $108.8 million, down from $120.4 million at the end of 2024 [9][26] Strategic Initiatives - The company is focused on building commercial momentum in minimally invasive glaucoma surgery (MIGS) and establishing equitable reimbursement for TearCare, alongside advancing its product pipeline [3][10] - The recent launch of OMNI Edge at the ASCRS Annual Meeting is part of the company's strategy to enhance its product offerings [7][10]
Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025
Globenewswire· 2025-04-24 20:05
Core Viewpoint - Sight Sciences, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, with a conference call scheduled to discuss the results [1] Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative interventional solutions to improve patient care and address prevalent eye diseases [3] - The company's OMNI® Surgical System is designed for glaucoma surgery, indicated for reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical Instrument is a bladeless device used in ophthalmic procedures to excise trabecular meshwork [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]
Sight Sciences Announces the Release of its Sustainability Report
Globenewswire· 2025-04-23 20:05
Core Insights - Sight Sciences, Inc. has published its second annual Sustainability Report, emphasizing its commitment to corporate sustainability and enhanced disclosures, including emissions reporting [2][6] Environmental Initiatives - The report details the company's efforts to reduce its environmental footprint through energy efficiency, waste reduction, and sustainable practices, including emissions reporting [3][8] - In 2024, the company reported Scope 1 emissions of 7,655 kg CO₂ and Scope 2 emissions of 32,125 kg CO₂, along with a subset of Scope 3 emissions totaling 2,169,524 kg CO₂ [8] Social Responsibility - The report provides insights into initiatives supporting community engagement, diversity, equity, and inclusion, as well as employee well-being [4] - Voluntary staff turnover decreased to 14% in 2024 from 19% in 2023, and over 50% of the workforce is comprised of women [8] - The company expanded its Women in Leadership initiative and increased the percentage of women in management positions to over 39% as of December 31, 2024, up from 37% in 2023 [8] Governance Practices - The report discloses the company's governance framework, ethical standards, and commitment to transparency and accountability, including information security breach reporting [5][8]
Sight Sciences Appoints Gary Burbach to its Board of Directors
Globenewswire· 2025-04-22 20:05
MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very ...